![](/assets/img/rmlogo.png)
Search Clinical Trials
Sponsor Condition of Interest |
---|
Consortium for Optimized Integration of Bio-Artificial Blood Components for Adaptive Resuscitation Therapy
University of Maryland, Baltimore
Hemorrhage
Hemodynamic Instability
There is need for a whole blood analog for use when banked blood is unavailable or
undesirable.
In civilian trauma, hemorrhage accounts for ~ 35% of pre-hospital deaths; moreover, ~ 20%
of military casualties are in hemorrhagic shock on arrival to field hospitals and an
additional 5% require urgent... expand
There is need for a whole blood analog for use when banked blood is unavailable or undesirable. In civilian trauma, hemorrhage accounts for ~ 35% of pre-hospital deaths; moreover, ~ 20% of military casualties are in hemorrhagic shock on arrival to field hospitals and an additional 5% require urgent transfusion. A recent review concluded that hemorrhage accounted for ~ 90% of potentially survivable battlefield deaths - lives that could be saved with better hemorrhage control capabilities and improved, field-ready blood, blood components, or blood substitutes. While study of ideal composition for resuscitative fluids is ongoing, it is evident that for those in hemorrhagic shock, volume replenishment alone (without O2 carrying capacity) is insufficient. Alternatively, with massive blood loss or with ongoing bleeding from non-compressible injuries, resuscitation with an O2 carrier alone may be complicated by acquired coagulopathy (either dilutional or trauma-induced). Development of a balanced resuscitation fluid that treats both shock and coagulopathy (comprising a field-deployable O2 carrier with lyophilized humoral hemostatic components and platelets) is essential to allow on-scene treatment during the critical 'golden-hours' after injury. As such, the whole blood analog described herein could be this product, thus transforming care in both civilian and military settings.The scientific purpose of this study is to develop a combined whole blood substitute from individual artificial prototypes that have been separately developed for each blood component (i.e., combining an artificial oxygen carrier, with an artificial plasma analogue and an artificial platelet analogue). Together, these combined components will recapitulate the composition and performance of natural whole blood. Blending and combination experiments of the individual artificial prototypes will be performed to test compatibility and optimize efficacy. State of the art in vitro (bench top) assays will be performed to assess physicochemical and functional performance (hemodynamics, oxygen delivery, hemostasis), with data being compared to experiments performed on fresh and stored whole blood. Type: Observational Start Date: Apr 2023 |
ROSE-Longitudinal Assessment With Neuroimaging
University of Cincinnati
Intracerebral Hemorrhage
The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE
study of cases with deep and lobar intracerebral hemorrhage to perform advanced
neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function
at baseline, 6 months after baseline, and 12... expand
The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE study of cases with deep and lobar intracerebral hemorrhage to perform advanced neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function at baseline, 6 months after baseline, and 12 months after baseline to determine predictors of recovery, progressive cognitive or functional impairment. The investigators propose to leverage the recruitment, DNA, RNA-seq and baseline advanced neuroimaging cohort of ROSE to obtain long-term neuroimaging and identical assessments longitudinally to address critical questions regarding the progressive decline of patients 12 to 24 months post intracerebral hemorrhage (ICH) with long term cognitive follow-up to 36 months on average. This proposal would represent the largest, and longest advanced neuroimaging and RNA-sequencing evaluation after ICH to date. Type: Observational Start Date: Sep 2020 |
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
Centinel Spine
Symptomatic Cervical Disc Disease
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and
prodisc C Vivo to the control, a similar, legally marketed total disc replacement device
in subjects with symptomatic cervical disc disease (SCDD). expand
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD). Type: Interventional Start Date: Aug 2019 |
Pilot Testing the Check Up
University of Maryland, Baltimore
Cannabis Use Disorder
We propose to pilot test an adapted version of the Teen Marijuana Check Up (TMCU) for
persistent cannabis users with first episode psychosis (FEP) in Coordinated Specialty
Care (CSC). The adapted version of the TMCU will include tailoring to risks of persistent
cannabis use in FEP, providing education... expand
We propose to pilot test an adapted version of the Teen Marijuana Check Up (TMCU) for persistent cannabis users with first episode psychosis (FEP) in Coordinated Specialty Care (CSC). The adapted version of the TMCU will include tailoring to risks of persistent cannabis use in FEP, providing education on lower risk cannabis use, and adding a session to address collaborative planning to maintain CSC engagement and antipsychotic adherence and to reduce harm associated with cannabis use. Type: Interventional Start Date: Jan 2021 |
Dose Response of Epinephrine
University of Maryland, Baltimore
Diabetes Complications
Epinephrine is the principal physiologic defense against hypoglycemia in type 1 and
longer duration type 2 DM. Despite this, it is unknown how epinephrine regulates in-vivo
endothelial function and atherothrombotic balance in humans. The specific aim of our
study will be to determine the dose response... expand
Epinephrine is the principal physiologic defense against hypoglycemia in type 1 and longer duration type 2 DM. Despite this, it is unknown how epinephrine regulates in-vivo endothelial function and atherothrombotic balance in humans. The specific aim of our study will be to determine the dose response effects of the key ANS counterregulatory hormone epinephrine on endothelial function, fibrinolytic balance and pro-atherogenic inflammatory mechanisms in healthy humans. Type: Interventional Start Date: Jun 2016 |
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis
Prothena Biosciences Ltd.
Light Chain (AL) Amyloidosis
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care
compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis. expand
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis. Type: Interventional Start Date: Aug 2021 |
Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of...
Major Extremity Trauma Research Consortium
Post Operative Surgical Site Infection
The overall objective is to compare the effect of Vancomycin and Tobramycin powder
combined (treatment) to Vancomycin powder (control) in the reduction of post-fixation
infections of tibial plateau and tibial pilon fractures at high risk of infection
(collectively considered the "study injuries"). expand
The overall objective is to compare the effect of Vancomycin and Tobramycin powder combined (treatment) to Vancomycin powder (control) in the reduction of post-fixation infections of tibial plateau and tibial pilon fractures at high risk of infection (collectively considered the "study injuries"). Type: Interventional Start Date: May 2021 |
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
University of Maryland, Baltimore
Breast Cancer
More than three quarter of patients with breast cancer are treated by hormone pills
called tamoxifen and aromatase inhibitors (AIs). AIs are drugs that stop female hormone
production. This hormone production mostly happens in fat, muscle, and breast tissue in
postmenopausal women. The female hormone... expand
More than three quarter of patients with breast cancer are treated by hormone pills called tamoxifen and aromatase inhibitors (AIs). AIs are drugs that stop female hormone production. This hormone production mostly happens in fat, muscle, and breast tissue in postmenopausal women. The female hormone estrogen is an important hormone for the growth of breast cancer cells. Anastrozole (Arimidex®) and Letrozole (Femara®) are AIs that are approved by the Food and Drug Administration (FDA). They have been used since 2005 to treat women with early stage breast cancer. When given before surgery (neoadjuvant), both anastrozole and letrozole have been shown to successfully shrink breast cancer tumors in most patients. In over 50% of patients, anastrozole and letrozole when given for about 4 months also helped to improve surgery outcomes. On top of that, whether or not a patient responds to anastrozole and letrozole before surgery can help the doctor decide whether that patient needs additional chemotherapy. One of the things may influence the level of hormone is body weight. It has been previously shown that postmenopausal women with higher body fat have higher level of female hormone as well as an increased risk of breast cancer. This is likely due to an increase in aromatase activity in the fatty tissue. However, at the current time AIs are used at the same doses in all women with breast cancer no matter whether they have different body weight. Currently, we do not know for certain whether the same doses of AIs work as well in patients with higher body fat compared to patients with less body fat. The purpose of this study is to see if women with higher body fat respond differently to AI treatment compared to women with lower body fat. Type: Interventional Start Date: May 2015 |
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic...
Janssen Research & Development, LLC
Leukemia, Lymphocytic, Chronic, B-Cell
Small Lymphocytic Lymphoma
The purpose of this study is to evaluate the efficacy and safety of ibrutinib +
venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is
either proactively reduced or reactively modified in response to adverse events (AEs). expand
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs). Type: Interventional Start Date: Jan 2024 |
Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas
University of Maryland, Baltimore
Glioma
The purpose of this study is to examine the safety and feasibility of performing
hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess
the accuracy of hyperpolarized metabolic MRI to diagnose intermediate to patients with
infiltrating gliomas and examine the added... expand
The purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the accuracy of hyperpolarized metabolic MRI to diagnose intermediate to patients with infiltrating gliomas and examine the added utility of metabolic MRI over standard MRI imaging The FDA is allowing the use of hyperpolarized [1-13C] pyruvate (HP 13C-pyruvate) in this study. Up to 5 patients may take part in this study at the University of Maryland, Baltimore (UMB). Type: Interventional Start Date: Aug 2020 |
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Teligene US
Non-small Cell Lung Cancer
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of
Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon
EGFR Mutations Only, Including L861Q, G719X, and/or S768I) expand
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I) Type: Interventional Start Date: Sep 2022 |
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment...
InSightec
Movement Disorders
Neurology
Parkinsons Disease
This registry is a prospective, multicenter, international, single arm, observational
post-approval registry with follow-up at 3, 6, and 12 months, and annually for 5 years.
The proposed registry will enroll 60 subjects and will be conducted at approximately 10
centers worldwide. expand
This registry is a prospective, multicenter, international, single arm, observational post-approval registry with follow-up at 3, 6, and 12 months, and annually for 5 years. The proposed registry will enroll 60 subjects and will be conducted at approximately 10 centers worldwide. Type: Observational [Patient Registry] Start Date: Jan 2023 |
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2-...
SynDevRx, Inc.
HR+/HER2-negative Breast Cancer
Metastatic Breast Cancer
This is a Phase 1b/2, open-label, parallel-arms pilot study in post-menopausal women with
hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an
alteration in the PI3K pathway, including a mutation of the PIK3CA gene, PTEN loss, or
AKT1 mutation, designed to determine... expand
This is a Phase 1b/2, open-label, parallel-arms pilot study in post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an alteration in the PI3K pathway, including a mutation of the PIK3CA gene, PTEN loss, or AKT1 mutation, designed to determine the safety of evexomostat (SDX-7320) plus standard of care treatment alpelisib (BYL-719) or capivasertib and fulvestrant (each combined, the 'triplet therapy'), to measure the severity and number of hyperglycemic events, and to assess clinical, anti-tumor benefit of the triplet therapy. The purpose of this study is: - to characterize the safety of the triplet drug combination consisting of either alpelisib or capivasertib (per the treating oncologist's choice) and fulvestrant plus evexomostat, - to test whether evexomostat, when given in combination with either alpelisib or capivasertib and fulvestrant will reduce the number and severity of hyperglycemic events and/or reduce the number or dose of anti-diabetic medications needed to control the hyperglycemia for metabolically normal patients and those deemed at risk for capivasertib and alpelisib-induced hyperglycemia (insulin resistance, as measured by HOMA-IR, baseline elevated HbA1c or well-controlled type 2 diabetes), and - to assess preliminary anti-tumor efficacy for each combination and changes in key biomarkers and quality of life in this patient population. Type: Interventional Start Date: Aug 2022 |
Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors
InSightec
Glioblastoma
Glioma
Liquid Biopsy
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain
barrier disruption with Exablate Model 4000 Type 2.0/2.1 for liquid biopsy in subjects
with suspected Glioblastoma brain tumors expand
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for liquid biopsy in subjects with suspected Glioblastoma brain tumors Type: Interventional Start Date: Aug 2022 |
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
Johns Hopkins University
Gram-negative Bacteremia
The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is
a multi-center, randomized clinical trial that hypothesizes that early transition to oral
antibiotic therapy for the treatment of Gram-Negative BloodStream Infection (GN-BSI) is
as effective but safer than remaining... expand
The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of Gram-Negative BloodStream Infection (GN-BSI) is as effective but safer than remaining on intravenous (IV) antibiotic therapy for the duration of treatment. Type: Interventional Start Date: Feb 2024 |
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
Massachusetts General Hospital
Cognitive Impairment
Dementia
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) is
an NIH-funded consortium dedicated to finding biomarkers involved in age-related thinking
and memory problems. Alzheimer's disease and other dementias leave signatures on brain
scans or in the blood called biomarkers.... expand
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) is an NIH-funded consortium dedicated to finding biomarkers involved in age-related thinking and memory problems. Alzheimer's disease and other dementias leave signatures on brain scans or in the blood called biomarkers. The MarkVCID study will measure a panel of candidate biomarkers in 1800 participants and watch them closely to see what they tell us about changes in brain function and risk of memory loss. Age-related problems in thinking and memory represent some of the greatest risks to public health in the US and globally. Diseases that affect small blood vessels in the brain have been shown to be major contributors to these changes. However, research and patient care can be held back by limited biomarkers that identify who should be treated. The MarkVCID Consortium includes 17 US medical centers, a Coordinating Center, an External Advisory Committee, and NIH leadership. Data and biospecimens collected as part of this research study will be stored in a research database and biorepositories, so that researchers can use this information to study brain function. Type: Observational Start Date: Sep 2021 |
Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells
University of Illinois at Chicago
Mesenchymal Stromal Cells
Cornea
Safety
Corneal Defect
This study is a longitudinal assessment using a classic dose-escalation study design to
assess the safety and maximal tolerated dose (MTD) of locally delivered allogeneic
mesenchymal stromal cells (MSC) for promoting corneal repair. The study will be conducted
at Illinois Eye and Ear Infirmary located... expand
This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of locally delivered allogeneic mesenchymal stromal cells (MSC) for promoting corneal repair. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will use digital conjunctival and corneal photography and corneal Scheimpflug Imaging, densitometry, and pachymetry for assessment of safety and corneal wound healing. Type: Interventional Start Date: Mar 2021 |
CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera
University of Maryland, Baltimore
Typhoid and/or Cholera Vaccination
This is an open-label, non-randomized study. The purpose of this study is to better
understand how vaccines against typhoid fever and cholera affect the normal immune system
and bacteria in the intestine. Patients having standard-of-care endoscopies (colonoscopy
and/or esophagogastroduodenoscopy (EGD))... expand
This is an open-label, non-randomized study. The purpose of this study is to better understand how vaccines against typhoid fever and cholera affect the normal immune system and bacteria in the intestine. Patients having standard-of-care endoscopies (colonoscopy and/or esophagogastroduodenoscopy (EGD)) will be divided into 3 groups: Group 1: Vivotif typhoid vaccination and/or Vaxchora cholera vaccination then endoscopy Group 2: Endoscopy, then Vivotif typhoid vaccination and/or Vaxchora cholera vaccination, then follow-up endoscopy Group 3: Endoscopy without vaccination. Both vaccines used in this study are licensed by the Food and Drug Administration (FDA) for travelers to developing countries. Volunteers will be asked to donate tissue, blood, saliva and stool samples for studying how the body responds to the typhoid and/or cholera vaccine. Type: Interventional Start Date: Nov 2018 |
Recovery and Outcomes From Stroke
University of Cincinnati
Intracerebral Hemorrhage
The investigators will perform follow-up on 500 cases of deep and lobar intracerebral
hemorrhage to perform advanced neuroimaging before 45 days post stroke, and evaluations
of motor and cognitive function at baseline, 3 months and 6 months to determine
predictors of recovery, progressive cognitive... expand
The investigators will perform follow-up on 500 cases of deep and lobar intracerebral hemorrhage to perform advanced neuroimaging before 45 days post stroke, and evaluations of motor and cognitive function at baseline, 3 months and 6 months to determine predictors of recovery, progressive cognitive or functional impairment. Type: Observational Start Date: Aug 2017 |
Cardiopulmonary Bypass Induced Red Blood Cell Lysis
University of Maryland, Baltimore
Cardiopulmonary Bypass
Cardiac Surgery
Kidney Injury, Acute
Studying the dynamics of red blood cell lysis, pfH, protective proteins and organ injury,
limits will be set for safe levels of pfH following the use of CPB. These results will be
compared to existing laboratory-based methods for determining red blood cell damage to
predict CPB assist device safety.... expand
Studying the dynamics of red blood cell lysis, pfH, protective proteins and organ injury, limits will be set for safe levels of pfH following the use of CPB. These results will be compared to existing laboratory-based methods for determining red blood cell damage to predict CPB assist device safety. Further, results from the studies described in this proposal will help develop therapeutic strategies to benefit patients by early detection of pfH and clearance protein levels that occur during CPB. Type: Observational Start Date: Mar 2022 |
Diagnostic Stewardship for Ventilator Associated Pneumonia
University of Maryland, Baltimore
Ventilator Associated Pneumonia
The goal of this pragmatic cluster-randomized crossover trial is to test if less
unnecessary antibiotics are prescribed when the lab reports respiratory culture test
results in a specific way for patients who have respiratory cultures obtained, but do not
meet clinical criteria for ventilator associated... expand
The goal of this pragmatic cluster-randomized crossover trial is to test if less unnecessary antibiotics are prescribed when the lab reports respiratory culture test results in a specific way for patients who have respiratory cultures obtained, but do not meet clinical criteria for ventilator associated pneumonia (VAP). The main question it aims to answer is: Does a modified culture reporting intervention reduce unnecessary antibiotics for ventilated patients in the intensive care unit (ICU)? Researchers will compare antibiotic use outcomes between eligible patients whose test results are communicated using the modified reporting and those with standard reporting of results. Type: Interventional Start Date: Aug 2023 |
The Effects of Exercise on Quality of Life and Fluid Dynamics in Patients With Aortic Dissection
University of Maryland, Baltimore
Aortic Dissection
Aerobic exercise and physical activity improve patient health in patients in a variety of
aspects of life and disease. It also improves patients' mental well-being and quality of
life. However, the safety of this physical activity and its potential benefits remain
uncertain for patients after aortic... expand
Aerobic exercise and physical activity improve patient health in patients in a variety of aspects of life and disease. It also improves patients' mental well-being and quality of life. However, the safety of this physical activity and its potential benefits remain uncertain for patients after aortic dissection, a tear in the main blood vessel delivering blood to all of the body's organs. The goal of this study is to facilitate the translation of pre-clinical findings by the Principal Investigator and published literature that demonstrates light to moderate exercise is safe and beneficial in patients with thoracic aortic dissection. This will be accomplished by using both imaging-based analyses of aortic wall responses to a 3- month exercise program, patient surveys of quality of life metrics, functional fitness assessments, and clinical outcomes. Type: Interventional Start Date: May 2023 |
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and...
Theratechnologies
HIV Infections
Multi-Antiviral Resistance
The virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical
trials. This study will expand ibalizumab's clinical data set and allow a better
understanding of the virologic response durability on ARV regimens with or without
ibalizumab in a heterogeneous real-world patient... expand
The virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical trials. This study will expand ibalizumab's clinical data set and allow a better understanding of the virologic response durability on ARV regimens with or without ibalizumab in a heterogeneous real-world patient population. Additional data on the efficacy and safety of ibalizumab and its impact on patient reported outcomes will be captured until study end. Primary Objective: To evaluate the long-term efficacy, safety, and durability of ibalizumab in combination with other ARVs by comparing the virologic, immunologic and clinical outcomes of patients receiving ibalizumab treatment versus patients not receiving ibalizumab. Secondary Objective: To assess the efficacy of ibalizumab in combination with other antiretrovirals by comparing the virologic, immunologic, clinical and patient reported outcomes of patients before and after they receive ibalizumab treatment. To assess the long-term safety and tolerability of ibalizumab. Other Objectives: To assess risk factors/predictors of virologic and immunologic response. To assess efficacy and safety in special populations that enroll. Type: Observational Start Date: Mar 2022 |
Rare and Atypical Diabetes Network
University of South Florida
Diabetes Mellitus
Diabetes Mellitus Progression
Glucose Intolerance
Glucose Metabolism Disorders
Metabolic Disease
RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study
of atypical diabetes.
The objective of this study is to define new forms of diabetes and the unique mechanisms
underlying these forms of atypical diabetes. The specific aims are to:
1. Identify and enroll... expand
RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes. The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to: 1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes. 2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes. 3. Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes. Type: Observational Start Date: Sep 2020 |
Spinal Cord Injury Registry - North American Clinical Trials Network
Robert G. Grossman, MD
Spinal Cord Injury
The NACTN Spinal Cord Injury Registry is a network of clinical centers collecting
de-identified data from patients admitted through the Emergency Department of a NACTN
center at the time of injury with an initial (first time) spinal cord injury (SCI).
Information will be collected on the natural history... expand
The NACTN Spinal Cord Injury Registry is a network of clinical centers collecting de-identified data from patients admitted through the Emergency Department of a NACTN center at the time of injury with an initial (first time) spinal cord injury (SCI). Information will be collected on the natural history of SCI and course of treatment through the first 12 months from the date of injury or long as medically indicated. Data collected includes imaging information from CT or MRI scans, neurological and general medical outcome and rehabilitation evaluation. No intervention is given other than standard of care for spinal cord injury, intensive monitoring and frequent follow up care. Type: Observational Start Date: Jul 2005 |
- Previous
- Next